In RRMS patients, IL-17 levels were higher in serum and CSF (24) and IL-17-expressing CD4+ T cells were increased during relapses, while IFNγ-expressing CD4+ T cells remained stable (25). This evidence concerns the gene CD4 and relapsing-remitting multiple sclerosis.